UK launch for Mylan, Biocon insulin glargine biosimilar Semglee
Mylan and Biocon have announced the UK launch of Semglee – an approved biosimilar of reference medicine insulin glargine.
Read More
Tag: insulin glargine
Tentative US approval for Merck’s diabetes therapy
The US Food and Drug Administration has given a tentative green light to Merck & Co’s follow-on biologic basal insulin Lusduna Nexvue.
Read More
Sanofi’s new diabetes combo hits PhIII targets
A new diabetes combination therapy being developed by Sanofi has hit targets in two pivotal Phase III studies, showing a superior reduction in blood glucose compared to insulin glargine and versus lixisenatide.
Read More
- UK medicines regulator grants marketing authorisation to Enflonsia for RSV prevention
- Saphnelo approved in the US for subcutaneous self‑administration
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
